[go: up one dir, main page]

WO2021001860A1 - Compositions pharmaceutiques de boswellia serrata - Google Patents

Compositions pharmaceutiques de boswellia serrata Download PDF

Info

Publication number
WO2021001860A1
WO2021001860A1 PCT/IN2020/050586 IN2020050586W WO2021001860A1 WO 2021001860 A1 WO2021001860 A1 WO 2021001860A1 IN 2020050586 W IN2020050586 W IN 2020050586W WO 2021001860 A1 WO2021001860 A1 WO 2021001860A1
Authority
WO
WIPO (PCT)
Prior art keywords
boswellia serrata
powder
blend
tablets
boswellia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2020/050586
Other languages
English (en)
Inventor
Vijayendrakumar Virendrakumarji Redasani
Ritesh Anil Chavan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2021001860A1 publication Critical patent/WO2021001860A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the present invention relates to the pharmaceutical compositions of Boswellia serrata.
  • the present invention further relates to the Gastro resistant and / or colon targeted delivery composition of Boswellia serrata and combination.
  • Boswellia serrata contains chemical constituents, such as b-boswellic acid, acetyl- b-boswellic acid, l l-keto ⁇ -boswellic acid and acetyl- l l-keto ⁇ -boswellic acid (AKBA).
  • AKBA is an organic acid extract of plants of the Boswellia genus.
  • Boswellia serrata has been used in traditional Indian ayurvedic medicine for the treatment of a number of inflammatory diseases, including chronic colitis, ulcerative colitis, osteoarthritis, Crohn's disease, and bronchial asthma.
  • Boswellic acids The pentacyclic triterpenic acids isolated from the oleo gum resin of various Boswellia species are collectively called as Boswellic acids (BA).
  • the oleo gum resin obtained from Indian variety i.e. Boswellia serrata (Family - Burseraceae) is commonly known as Salai guggal.
  • the resin fraction of Salai guggal is rich in Boswellic acids and its essential oil is composed of a mixture of mono, di and sesquiterpenes while gum fraction chiefly contains pentose and hexose sugars.
  • This oleo-gum resin is quite popular among traditional practitioners of traditional Chinese and Indian Systems of medicine owing to their wide range of useful biological properties such as anti-inflammatory, anti-arthritic, antirheumatic, anti- diarrheal, anti-hyperlipidemic, anti-asthmatic, anti-cancer, anti-microbial anti fungal and analgesic activity, etc. It has been used as a herbal medicine since the prehistoric time to cure acute and chronic ailments including inflammatory diseases.
  • Example 16 of PCT publication number WO 2008059522 describes preparation of extended release boswellic acid pellets and tablets.
  • boswellic acid pellets are prepared by coating non-pareil seeds and the pellets were coated with Poly ethyl acrylate and methyl methacrylate (2:1) aqueous dispersion polymer.
  • the core tablets were prepared by using different super-disintegrants like Cross PVP and Sodium starch glycolate. The core tablet was then coated using a variety of enteric coated polymers like Eudragit S-100 and Cellulose acetate phthalate.
  • Boswellia serrata have numerous potential therapeutic applications, it has poor solubility and bioavailability. As a result, there is a great need in the medical and pharmaceutical industries to increase its solubility and bioavailability to improve its therapeutic efficacy.
  • First object is to provide solubilized compositions of Boswellia Serrata.
  • the second object is to provides Gastro resistant and / or colon targeted delivery composition of Boswellia serrata.
  • Third object is to provide simple processes to arrive at the Gastro resistant and / or colon targeted delivery composition of Boswellia serrata of the present invention.
  • the present invention provides solubilized compositions of Boswellia Serrata alone or with Curcumin containing from 5 - 35 % solubilizer.
  • the present invention provides Gastro resistant and / or colon targeted delivery composition of Boswellia serrata and combination with other actives such as Curcumin wherein the compositions do not release more than 10 % active in acidic media for 2 hrs and thereafter release at least 90 - 95 % in a media of 6.8 pH phosphate buffer over next 8 - 10 hrs.
  • various processes are provided such as direct compression, wet granulation, extrusion and hot melt extrusion to prepare these compositions.
  • Constipation and Irritable bowel syndrome is a chronic condition which the patient has to manage long term.
  • three types of IBS are found viz. constipation-predominant, diarrhea-predominant or mixed.
  • Various medications are approved for IBS and include
  • Medication to relax the colon and slow the movement of waste through the lower bowel for e.g. Alosetron;
  • Medications for increasing fluid secretion in your small intestine to help with the passage of stool for e.g. Lubiprostone and Linaclotide.
  • antibiotics such as Rifaximin can decrease bacterial overgrowth and diarrhea.
  • Natural medications such as certain herbs can manage IBS and provide side effects free treatment.
  • Herbs such as Boswellia Serrata when given orally would lose large dose before it reaches the site of action.
  • Curcumin from Curcumin Longa has exceptional natural healing properties and can produce synergistic action with IBS medication but again majority of the dose is lost before it reaches site of action because of less or no aqueous solubility.
  • Boswellia Serrata viz. Boswellic acids specifically AKB A is generally low i.e up to 30 -35 % of the powder. Some experiments to increase AKB A up to or more than 60 % are being attempted.
  • Boswellia Serrate powder has gummy nature and therefore, solubilizing AKBA from the powder is highly challenging task. Several solubilizers and their combinations are sometimes needed to cause rapid release of AKBA if large dose is able to reach at its site of action. Some Boswellia Powders and tablets which are available in the market do not seem to have included any agent or solubility modifier which can help to release until it reaches at the site of action and then ensure complete release.
  • the inventors of the present invention have come up with the novel formulations of Boswellia Serrata having therapeutically releasing AKBA and optionally Curcumin powder ensuring that both these natural herbs allow their respective natural actives to reach site of action in sufficient amounts and immediately and gradually releasing completely once they reach the site of action.
  • the present invention provides a composition comprising:
  • a core comprising boswellia serrata having therapeutically effective amount of AKBA, optionally curcumin and one or more solubilizing agents;
  • the present invention provides a composition comprising:
  • a core comprising boswellia serrata having therapeutically effective amount of AKBA, and one or more solubilizing agent;
  • the present invention provides a composition
  • a composition comprising: a) a core comprising boswellia and meglumine, an alkaline solublizer;
  • the present invention provides a composition comprising:
  • a core comprising boswellia serrata and meglumine, an alkaline solublizer; b) optionally, barrier or seal coating;
  • composition of the present invention may further comprise an additional active ingredient such as curcumin or therapeutically effective curcuminoids.
  • the present invention provides a composition
  • a composition comprising: a) a core comprising boswellia serrata having about 30 % AKBA and curcumin powder having about 20 % Curcumin and alkaline solublizer;
  • the amount of Boswellia Serrata powder in a composition will vary from 10 - 90 %, preferably from around 20 % to around 80 %. In an embodiment, amount of Boswellia Serrata Powder is 80.64. In another embodiment it is from 72-73 %. In yet another embodiment it is 59-60 %. One more embodiment has around 30 % of this powder. In yet another embodiment, the powder is 23 - 24 %. When AKBA content is higher than 30 %, lower amounts can be used. When AKBA content is 30 %, higher amounts such as more than 50 % is preferred.
  • the solubilizer or solubilizing agent plays a vital role in solubilizing active ingredient AKBA from the gummy powder of Boswellia Serrata. In the absence of a solubilizer, AKBA release is surprisingly reduced.
  • the solubilizing agent according to the present invention may be selected from but not limited to meglumine, Soluplus® [a polyethylene glycol, polyvinyl acetate and polyvinylcaprolactame -based graft copolymer (PVAc-PVCap- PEG)], SEPITRAPTM 80 [Polysorbate 80 (45-65%), Magnesium Aluminometasilicate (35- 55%)], Nu-RICE® (rice extract or rice bran extract from RIBUS, Inc.), vitamin E acetate (tocopherol), vitamin E TPGS (D -a-Tocopherol polyethylene glycol 1000 succinate), natural polymer Pullulan, poloxamer.
  • Soluplus® a polyethylene glycol, polyvinyl acetate and polyvinylcaprolactame -based graft copolymer (PVAc-PVCap- PEG)
  • SEPITRAPTM 80 Polysorbate 80 (45-65%), Magnesium Alumin
  • solubilizers are tried and such compositions are found to be highly desired.
  • combination of poloxamer 188 and meglumine is used.
  • meglumine is combined with vitamin TPGS.
  • meglumine and Pullulan are used.
  • Pullulan and Nu-RICE® have been employed.
  • solubilizer is from 5 - 35 %. In an embodiment, around 4 % meglumine and around 4 % Vitamin TPGS are used. In another embodiment, 12- 13 % of meglumine and around 4 % of poloxamer 188 re used. In yet another embodiment 11-12 % meglumine and 5 % Pullulan are used. An embodiment contained three solubilizers namely meglumine 13 - 14 %, vitamin E TPGS around 3 % and Nu-Rice® in 1.5 - 2 %.
  • Nu-Rice® being a natural ingredient, higher amounts such as 15 - 25 % are also employed and found to provide excellent compositions.
  • Nu-Rice® is a new natural emulsifier and solubilizer which is marketed by Ribus. It is a rice extract or rice bran extract prepared by a patented process to extract functional components of rice bran. It can be used even at a concentration from 0.25 %. Various concentrations such as from 1 - 2 % to 15 - 25 % have been tried.
  • a solubilizer is ascertained from the release of AKBA from the composition of Boswellia Serrata. Since the targeted drug delivery is designed, the tablets are coated with an enteric coat. Optionally, a barrier coat is applied on the tablets before subjecting to enteric coating. Enteric coated compositions are tested for release first in an acidic media of pH 1.2 followed by a buffer of alkaline pH such as preferably phosphate buffer of pH 6.8. Since targeted drug release is desired, it is ensured that not more than 10 % is released when tested in a medium of acidic pH. Thus, the desired release is not more than 10 % for first two hrs in a media of acidic pH and a complete release viz. at least 90 - 95 % over next 8 - 10 hrs, preferably over next 8 hrs.
  • the materials which may be incorporated in the barrier coating are natural or synthetic pharmaceutically acceptable materials such as sugar, sugar alcohols, polyethylene glycols, polyvinylpyrrolidones, polyvinyl alcohols, polyvinyl acetates, hydroxypropyl celluloses, methylcelluloses, ethylcelluloses, hydroxypropyl methylcelluloses, carboxymethyl cellulose sodium, water soluble salts of enteric coating polymers, and others, used alone or in mixtures.
  • This barrier coating may comprise various other additives such as plasticizers, colorants, pigments, fillers, anti-tacking and antistatic agents (such as magnesium stearate, titanium dioxide, and talc), and other additives.
  • Barrier coating may also comprise sodium, potassium, calcium or magnesium as their oxides, hydroxides, or salts.
  • glidants such as colloidal silicon dioxide and a novel ingredient Nu-Sorb® having Rice bran, Oat Fiber and Sunflower lecithin marketed by Ribus.
  • the core a) of the composition according to the present invention is subjected to a process of coating, for example in a coating pan, with a dispersion of a substance capable of forming a film resistant to gastric juices, to obtain the gastro-protection.
  • the enteric coating (b) comprises enteric polymer i.e. i) at least one or a combination of derivatives of methacrylic acid and methyl methacrylate with non limiting examples including EudragitTM LI 00, EudragitTM LI 2, 5, EudragitTM SI 00, EudragitTM S 12,5; ii) shellac (ShellacTM) or iii) methyl cellulose derivatives such as HPMC phthalate / Cellulose acetate phthalate or HPMC succinate.
  • enteric polymer i.e. i) at least one or a combination of derivatives of methacrylic acid and methyl methacrylate with non limiting examples including EudragitTM LI 00, EudragitTM LI 2, 5, EudragitTM SI 00, EudragitTM S 12,5; ii) shellac (ShellacTM) or iii) methyl cellulose derivatives such as HPMC phthalate / Cellulose acetate phthalate or HPMC succinate.
  • the gastroresistant coating typically comprises an enteric polymer such as one or more of cellulose derivatives, cellulose phthalates, succinates, methacrylic or polymethacrylic acid polymers, shellac or alginates, preferably of shellac and hydroxypropylmethylcellulose, or ethyl cellulose with alginic acid, or polymethacrylates (pH-dependent), ethylcellulose or hydroxypropylmethylcellulose (pH-independent), HPMC Acetate Succinate, EUDRAGUARD® (Evonik Industries AG).
  • the enteric coating may comprise various other additives such as plasticizers, colorants, pigments, fillers, anti-tacking and antistatic agents (such as magnesium stearate, titanium dioxide, and talc), and other additives.
  • the composition according to the invention is in the form of an enteric coated granule / tablet/ microtablet/dmg coated pellet or likes wherein the core a) is enclosed in the enteric film b), or of a gastro-resistant capsule wherein said core a) is enclosed in a hard or soft shell (layer b) that is enterically coated.
  • the amount of enteric coating varies from 3 - 12 %, preferably from 3 - 10 %. In an embodiment, around 8 % enteric coat containing around 6 % enteric polymer is employed.
  • a preferred enteric polymer is 2: 1 or 1 : 1 combination of Eudragit L 100 and Eudragit S 100.
  • Shellac is also preferred because it is natural polymer.
  • Shellac from 3 - 12 %, preferably from 3 - 8 % can be employed. In few embodiments, shellac is employed at concentrations of 3.5 % , 4.5 % and 6 %.
  • Plasticizers are used in amounts from 10 - 40 % of the enteric polymer and from 1 - 3 % of the compositions. Suitable plasticizers include triethyl citrate, polyethylene glycols etc. Combination of these two in a ratio of 1: 1 is most preferred. In few embodiments, 1.2 % , 1.4 % and 2 % plasticizers are used.
  • Talc is employed as anti-tacking agent from 0.5 - 2 % of the composition.
  • Batches F001 to F007 are manufactured in accordance with the present invention employing from around 60 % (59.55 %) - around 80 % (80.64 %) of Boswellia Serrata powder with 30 % AKBA and two solubilizers.
  • the core tablets are coated with an enteric coating using either the combination of Eudragit L100 and Eudragit S 100 in 2: 1 or 1:1 proportion or using Shellac natural polymer.
  • Curcumin powder containing at least 20 % water soluble curcumin is used in addition to Boswellia Serrata.
  • the two actives can be used in ratios from 1 :5 to 5: 1 with a preferred ratio from 1 : 1 to 4: 1.
  • a composition having 60 % of actives 30 % of Boswellia Seratta and 30 % of Curcumin powder (having 20 % of Curcumin) have been employed.
  • Another combination is 60 % of Boswellia Serrata and 15 % of Curcumin powder.
  • Yet one more combnation is 60 % of Boswellia Seratta and 20 % of Curcumin powder.
  • a batch F008 with two actives viz. Boswellia Serrata (Containing 30 % AKBA) and Curcumin powder 30 % (containing about 20 % water soluble Curcumin) is manufactured in accordance with the present invention and tested for % Cumulative release to ensure compliance.
  • the release is not more than 10 % in acidic media followed by at least 90 - 95 % release in next 8 - 10 hrs in a buffer of alkaline pH.
  • the dissolution conditions employed are as follows:
  • the present invention provides a method for the preparation of pharmaceutical composition comprising boswellia serrata and
  • composition comprising the steps of:
  • the present invention provides a method for the preparation of pharmaceutical composition comprising boswellia serrata
  • composition comprising the steps of:
  • the present invention provides a method for the preparation of pharmaceutical composition comprising boswellia serrata
  • composition comprising the steps of:
  • compositions of the present invention include - Granulation or Extrusion or Hot melt Extrusion.
  • meglumine and poloxamer When meglumine and poloxamer are used, they are generally blended with dry ingredients followed by granulation. Vitamin E TPGS and Pullulan are added to hot water and allowed to come to room temperature. After blending of dry ingrdients, the solution is used for granulation.
  • solubilizer is added to dry ingredients and blended to get a mass.
  • the mass is passed through the twin scree extruder at Temp NMT 150 Deg C. and the extruded material is collected and milled into the fine granular particles.
  • a direct compression process is employed by mixing all dry ingredients and compressing the blend into tablets.
  • the compressed tablets are optionally barrier coated and further subjected to enteric coating.
  • the composition of the present invention can be in one of the following forms: an enteric coated tablet, an enteric coated granule, an enteric coated pellets which are drug coated before applying the enteric coat, tablet comprising an enteric coated pellets which are drug coated before applying the enteric coat, a capsule comprising enteric-coated granules or microtablets, or pellets or a hard or soft capsule with a gastro-resistant coating comprising the core a) in the form of powder, granules, micropellets, solution or suspension.
  • the layer b) is an enteric film directly coating said core a), i.e. an enteric film enclosing the core and applied directly on the core.
  • the layer b) is an enteric film coating barrier coated core a), i.e. an enteric film enclosing the barrier coated core and applied on the barrier coated core.
  • compositions according to the invention modulate the activity of bowsellia, reducing its frequency of administration and modulating its release in particular sites of the gastrointestinal tract.
  • compositions according to the invention are useful in the treatment of inflammatory diseases, including chronic colitis, ulcerative colitis, arthritis, Crohn's disease and can be given as Once a Day Therapy.
  • compositions according to the invention are useful in the treatment of intestinal disorders of inflammatory, immunological and/or systemic origin, in particular in the treatment of gastrointestinal disorders, irritable bowel syndrome, Crohn's disease and ulcerating colitis or in constipation.
  • the gastroresistant coating of the core prevents release in vitro for at least one hour under conditions of pH less than 6.0, preferably less than 5.5 and most preferably less than 5.
  • the gastroresistant coating of the core prevents release in vitro for at least 2 hours under conditions of pH ⁇ 1.2 - 4.5.
  • the core is coated with a quantity of polymer/resin sufficient to guarantee that it remains substantially intact in gastric for at least 2 hours before the release of the active ingredient from the core (lag time).
  • the system prevents early release of boswellia serrata (AKBA) during the stomach-jejunum transit time, and help for the targeted and complete release the medicament in the intestine.
  • AKBA boswellia serrata
  • compositions according to the invention therefore are delayed-release forms (gastroresistant with lag time), which can reach the distal part of the ileum and/or the initial part of the colon substantially unchanged and thereafter rapidly release the active constituents.
  • compositions according to the invention contain a unit dose ranging between 50 to 1200 mg of active ingredient boswellia, preferably 100 to 1000 mg of active ingredient boswellia and most preferably 250 to 500 mg of active ingredient boswellia.
  • the weight ratio between boswellia and solubilizing agent ranges between 1: 10 and 10: 1. Preferably from 1: 1 to 10: 1. In an embodiment, it is 3:2, in another embodiment it is 2.4 : 1. In yet another embodiment, it is from 1:3.2.
  • compositions according to the invention can also contain other excipients, such as diluents, binders, wetting agents, ionic or non-ionic surfactants, disintegrating agents, super-disintegrating agents, crosslinked polymers, complexing agents and lubricants.
  • excipients such as diluents, binders, wetting agents, ionic or non-ionic surfactants, disintegrating agents, super-disintegrating agents, crosslinked polymers, complexing agents and lubricants.
  • excipients examples include phosphatides, lecithins, sodium lauryl sulphate, sorbitan esters, sucrose palmitate, sodium lauryl sarcosinate, cholic acids, poloxamer, cyclodextrins, starches, sodium starch glycolate, croscarmellose and cro s slinked polyvinylpyrrolidones .
  • the compositions according to the invention maximise the pharmacological effect of Boswellia serrata or its constituents such as AKBA in the treatment of irritable bowel syndrome, due to their ability to carry the active ingredient and specifically release it in the colon.
  • compositions according to the invention are therefore particularly useful for the treatment of acute and chronic gastrointestinal disorders such as irritable bowel syndrome, diarrhoea, constipation, Crohn's disease, ulcerating colitis, diverticulitis and inflammatory bowel disease in general.
  • compositions according to the invention can be prepared using conventional techniques such as direct compression, wet granulation, and dry compacting /granulation and melt granulation.
  • the product with the addition of excipients such as wetting agents, surfactants, disintegrating agents, super-disintegrating agents, glidants, non-stick agents or lubricants is then prepared using a suitable wet or dry granulation technique, direct division, direct compression, co-grinding, melt granulation or extrusion granulation.
  • excipients such as wetting agents, surfactants, disintegrating agents, super-disintegrating agents, glidants, non-stick agents or lubricants is then prepared using a suitable wet or dry granulation technique, direct division, direct compression, co-grinding, melt granulation or extrusion granulation.
  • the other ingredients include diluents up to 50%, lubricants (0.01-3%), glidants (0.01-3%), disintegrating and super-disintegrating agents (0 - 40%) and complexing agents (0 - 40%) may be added to this mixture.
  • the outer coating essentially consisting of materials possessing gastroresistance properties is then applied to the core thus obtained.
  • the said process of coating could be any of the process of applying a coat known in the art.
  • enteric coating or enteric coating layer means a layer, forming a continuous barrier, that consists of substances that are resistant to the acidic gastric juices and dissolve in the upper intestinal tract.
  • Said enteric coating layer may be applied directly on the core (e.g. to obtain a filmed tablet or granule) or may be in the form of a shell (e.g. an enteric-coated hard or soft capsule shell comprising the core a), which encloses said core in the form of powder or of one or more tablets, granules or micro-pellets.
  • enteric film or“enteric coat” means a coat that is preferably applied directly on the core, i.e. it adheres to the core, and is capable of protecting the composition from the action of the gastric juices in the stomach and to release the active principle in the upper intestine.
  • enteric coating is applied on the barrier coated cores.
  • compositions and methods comprise use of Boswellia (Boswellia serrata) extract or any components found in Boswellia extract, including but not limited to boswellic acid and pentacyclic triterpene acids.
  • Boswellia Boswellia serrata
  • components include, but are not limited, to a-boswellic acid, b-boswellic acid, 3- acetyl a-boswellic acid, 3-acetyl b-boswellic acid, l l-keto ⁇ -boswellic acid (KB A) and acetyl- l l-keto ⁇ -boswellic acid (AKBA).
  • the preferred component is acetyl- 11 -keto ⁇ -boswellic acid (AKBA).
  • Example 1 provides three core compositions according to the present invention under table I and dissolution profiles of the said three compositions under table II.
  • Example 2 provides additional three core compositions according to the present invention under table III and dissolution profiles of the said three compositions under table IV.
  • Example 3 provides three more compositions of Boswellia Serrata for Colon Targeted Delivery under table V and corresponding dissolution profiles under table VI-A and VI-B using a buffer of pH 1.2 for 2 hrs followed by buffer of pH 6.8 for next 3 hrs. It is noted that enteric coated compositions of the present invention for colon targeted delivery have achieved
  • Boswellia serrata (AKBA-30) powder, meglumine, poloxamer and colloidal silicon oxide were mixed in a blender. The blend was granulated in a granulator. The granules were mixed with colloidal silicon oxide and compressed into tablet.
  • Table III Compositions 4, 5 and 6.
  • Boswellia serrata (AKBA-90) powder, meglumine, poloxamer and colloidal silicon oxide were mixed in a blender. The blend was granulated in a granulator. The granules were mixed with colloidal silicon oxide and compressed into tablet. Table IV: Dissolution profiles of compositions 4, 5 and 6.
  • Table V Compositions of Boswellia Serrata for Colon Targeted Delivery
  • Boswellia serrata (AKBA-30) powder, meglumine, poloxamer and colloidal silicon oxide were mixed in a blender. The blend was granulated in a granulator. The granules were mixed with colloidal silicon oxide and compressed into tablet. Polyethylene glycol 6000, Eudragit L 100, Eudragit S 100 and talc were dispersed in purified water to form a coating solution. The compressed tablets were coated with coating solution at Bed temperature NMT 40° C in coating pan. Table VI-A - Dissolution profiles of Colon Targeted Delivery Compositions 7, 8 and 9 in pH 1.2 buffer for first 2 hrs.
  • Time points 30, 60, 90, 120 and 180 minutes from start.
  • Example 4 Table VI : Compositions of Boswellia Serrata for Colon Targeted Delivery and % Cumulative release in a media of acidic pH for 2 hrs followed by release in an alkaline phosphate buffer of pH 6.8.
  • Step 2 material Granulate the Step 2 material in RMG or twin-screw granulation and collect the wet mass.
  • step 7 compress tablets using the dispersion from step 9.
  • Step 2 material in RMG or twin-screw granulation using step 3 solution and collect the wet mass.
  • step 9 compress tablets using the dispersion from step 11.
  • Step 2 material in RMG or twin-screw granulation using step 3 solution and collect the wet mass.
  • step 9 compress tablets using the dispersion from step 11.
  • step 9 compress tablets using the dispersion from step 11.
  • step 9 compress tablets using the dispersion from step 12.
  • step 5 Pass the granules from step 5 through 30 mesh.
  • step 8 compress tablets using the dispersion from step 11.
  • step 4 compress tablets using the dispersion from step 8.
  • step 4 compress tablets using the dispersion from step 8.
  • Post coating dry the tablets for 30 min at NMT 40Deg C.
  • Example 5 Table VI : Compositions of Boswellia Serrata with all natural ingredients for Colon Targeted Delivery (Less than 5 % synthetic chemicals)
  • step 2 Mix the step 2 and step 3 material in blender and blend for 30 min in suitable blender.
  • step 6 compress tablets using the dispersion from step 9.
  • Example 6 Table VII : % Cumulative release of AKBA and Curcumin in a media of acidic pH for 2 hrs followed by release in an alkaline phosphate buffer of pH 6.8.
  • Dissolution Conditions Dissolution in 900 ml media with Type II apparatus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

: L'invention concerne des compositions solubilisées de Boswellia Serrata seule ou avec de la curcumine contenant de 10 à 90 % de Boswellia Serrata et de 5 à 35 % d'un ou de plusieurs agents de solubilisation. L'invention concerne en outre une composition d'administration gastro-résistante et/ou ciblée au colon de Boswellia Serrata et une combinaison avec d'autres substances actives telles que la curcumine, les compositions étant revêtues d'un polymère entérique et ne libérant pas plus de 10 % de substance active dans des milieux acides pendant 2 heures, puis libérant au moins 90 à 95 % dans un milieu d'un tampon phosphate à pH 6,8 pendant environ 8 à 10 heures. L'invention concerne également divers procédés tels que la compression directe, la granulation par voie humide, l'extrusion et l'extrusion à chaud pour préparer ces compositions.
PCT/IN2020/050586 2019-07-04 2020-07-04 Compositions pharmaceutiques de boswellia serrata Ceased WO2021001860A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921026903 2019-07-04
IN201921026903 2019-07-04

Publications (1)

Publication Number Publication Date
WO2021001860A1 true WO2021001860A1 (fr) 2021-01-07

Family

ID=74100485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2020/050586 Ceased WO2021001860A1 (fr) 2019-07-04 2020-07-04 Compositions pharmaceutiques de boswellia serrata

Country Status (1)

Country Link
WO (1) WO2021001860A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666535B2 (en) * 2018-09-26 2023-06-06 Inventia Healthcare Limited Curcuminoid composites

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN201621016785A (fr) * 2016-05-13 2017-11-17

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN201621016785A (fr) * 2016-05-13 2017-11-17

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE TKDL 1920, "Nuska-e- Qator", Database accession no. AH5/2664 *
HAROYAN, ARMINE ET AL.: "Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study", BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 18, no. 1, 7, 9 January 2018 (2018-01-09), pages 1 - 16, XP021252461 *
PANDEY, VIKAS ET AL.: "Granulated colloidal silicon dioxide-based self-microemulsifying tablets, as a versatile approach in enhancement of solubility and therapeutic potential of anti-diabetic agent: formulation design and in vitro/in vivo evaluation", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 43, no. 6, 3 June 2017 (2017-06-03), pages 1023 - 1032, XP055783817 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666535B2 (en) * 2018-09-26 2023-06-06 Inventia Healthcare Limited Curcuminoid composites

Similar Documents

Publication Publication Date Title
JP4088413B2 (ja) 腸管を処置・治療するペレット製剤
US5316772A (en) Bilayered oral pharmaceutical composition with pH dependent release
JP3725542B2 (ja) ピコサルフェート剤形
JP3725539B2 (ja) ビサコジル剤形
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
DE69721559T2 (de) Geschmacksmaskierte pharmazeutische dosisform mit schneller freisetzung
JP3633936B2 (ja) センナ剤形
JPH09502738A (ja) 制御放出のための新規ビーズおよびそれらを含有する医薬製剤
KR102391496B1 (ko) 탐수로신 염산염 함유 서방성 펠렛을 포함하는 용출률이 제어된 경구투여용 약제학적 제제
EP3079673B1 (fr) Systèmes thérapeutiques à libération modifiée pour l'administration par voie orale de menthol dans le traitement de troubles intestinaux
WO1999016448A1 (fr) Comprime de theophylline a liberation prolongee
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
CN1237908A (zh) 用于结肠给药的具有多层肠溶聚合物包衣的比沙可啶剂型
WO2009101658A1 (fr) Préparation pharmaceutique à libération programmée
WO2009101656A1 (fr) Préparation à libération retardée
WO2021001860A1 (fr) Compositions pharmaceutiques de boswellia serrata
CN114845705A (zh) 用于治疗胃肠疾病的口服固体大麻素油组合物
WO2017146053A1 (fr) Particules de composition pharmaceutique et préparation se délitant par voie orale comprenant celles-ci
JPWO2017146052A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
JP3122478B2 (ja) 下部消化管放出型経口製剤
JP4864024B2 (ja) 時限放出製剤
WO2005077357A1 (fr) Composition pharmaceutique contenant un complexe de platine en tant que substance active, et son procede de production
JP7182550B2 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2025215658A1 (fr) Compositions pharmaceutiques de kétotifène
CN1929838B (zh) 含有难溶于水的药物的固体制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20834852

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20834852

Country of ref document: EP

Kind code of ref document: A1